Status:
RECRUITING
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Cancer Prevention Research Institute of Texas
Conditions:
Cancer
Fatigue
Eligibility:
All Genders
18-39 years
Phase:
NA
Brief Summary
The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.
Detailed Description
Primary Objective: Test the efficacy of RISE-YA to improve CRF Secondary Objectives: 1. Test the efficacy of RISE-YA to improve PA and physical function in fatigued YA brain tumor survivors. 2. Det...
Eligibility Criteria
Inclusion
- Is currently between the ages of 18-39 years
- Their primary brain tumor was diagnosed at age 15-39 years
- Is 6 months to \<5 years post curative treatment
- Has been treated with chemotherapy and radiation, given most patients receive both therapies.
- Functional Assessment of Chronic Illness therapy (FACIT)-Fatigue ≤ 43. FACIT-Fatigue will be used as a screener because this 13-item scale can be completed relatively quickly in clinic
- Currently engage in \<150 minutes of PA and \< 2 sessions of muscle strengthening exercise per week (assessed by Godin Leisure-Time PA Questionnaire)
- Must be able to speak, write, and read English
- No exercise contraindication as assessed by screening with the Physical Activity Readiness Questionnaire PAR-Q+. In addition, participants' care teams will be notified of their participation in the study.
- Must be able to provide informed consent/assent.
Exclusion
- Non-English speaking
- Screen failure for exercise safety
- Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
- Recent fracture or acute musculoskeletal injury that precludes ability to participate in supervised exercise training sessions
- History of underlying chronic disease, secondary malignances, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain
- Cognitive and/or major sensory deficits that would impede the completion of research activities and assessments as deemed by the clinical team.
- Self-report of pregnancy
- Prisoners
- Documented developmental disorders (e.g., Autism) or major psychotic illness (e.g., schizophrenia)
Key Trial Info
Start Date :
September 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT07186556
Start Date
September 9 2025
End Date
December 31 2031
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030